Current Treatment Strategies for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Clinical Diabetes and Endocrinology- United Kingdom

doi 10.1186/s40842-018-0066-3

Full Text

Abstract

Available in

Categories

Date

July 11, 2018

Authors

Simona Grozinsky-Glasberg

Publisher

Springer Science and Business Media LLC

Related search

Circulating Markers in Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)

Dutch

Comprehensive Genomic Profiling of 724 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

Journal of Clinical Oncology

Cancer Research

English

Catecholamine Production in Patients With Gastroenteropancreatic Neuroendocrine Tumors

European Journal of Endocrinology

English

Resistance to Targeted Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Endocrine-Related Cancer

Cancer Research

English

Identification of Primary Tumors in Patients Presenting With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

English

Lanreotide vs Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Observational Time and Motion Analysis

Journal of Oncology Pharmacy Practice

English

Risk Factors Associated With Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in a Cohort of 2.3 Million Israeli Adolescents

International Journal of Cancer

Cancer Research

English

Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature

International Journal of Surgical Oncology

English

MicroRNA Analysis of Gastroenteropancreatic Neuroendocrine Tumors and Metastases

English